Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.

Clinical Breast Cancer(2020)

引用 8|浏览25
暂无评分
摘要
Our real-life data highlight a different risk of eBC recurrence after grouping patients according to HR status and BMI. These results might help clinicians to identify correct treatment strategies. Patients who are HR and have BMI ≥25 might benefit from escalation approaches, whereas those who are HR and have BMI <25 might be eligible for a shorter duration of adjuvant treatment with anti-HER2 agents.
更多
查看译文
关键词
Body mass index,Early breast cancer,HER2,Hormone receptors,Trastuzumab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要